Envision Healthcare Corp. (EVHC - Free Report) reported second-quarter earnings of 79 cents per share, surpassing the Zacks Consensus Estimate by 5.33%, but declining from $1.01 reported in the year-ago quarter.
The company reported net revenue of $1.95 billion, which missed the Zacks Consensus Estimate by 0.5% but increased from $758.5 million in the year-ago quarter.
Total operating expenses of $1.75 billion increased from $600 million in the year-ago quarter.
Net revenues from the Physician Services segment were $1.63 billion in the second quarter of 2017, reflecting an increase of 9.3% year over year. The revenue growth was driven by 10.6% contribution from acquisitions and 2.5% from same contracts.
Net revenues from Ambulatory Services were $318.5 million, reflecting a decline of 0.4% year over year. Same-center revenues increased 0.6%, comprising a 0.5% increase in net revenue and a 0.1% increase in procedure volume.
Envision Healthcare had cash and cash equivalents of $441.3 million, up from $316.9 million as of Dec 31, 2016.
Total long-term debt increased to $6.3 billion as of Jun 30, 2017 from $5.8 billion as of Dec 31, 2016.
The company’s ratio of total net debt at Jun 30, 2017 to trailing 12-month EBITDA as calculated under the company’s credit agreement was 4.5 times.
Envision Healthcare Corporation Price, Consensus and EPS Surprise
For 2017, the company lowered its revenue guidance to $7.75–$8.00 billion (from the previous guidance of $7.80 billion to $8.05 billion), adjusted EBIDTA to $1.02 billion to $1.04 billion (from $1.038 billion to $1.066 billion) and adjusted EPS to $3.35 to $3.45 (from $3.38 to $3.52).
It, however, kept intact, the same contract revenue growth guidance of 3% to 4% in the physician services segment and 0% to 1% in ambulatory services.
For the third quarter, the company expects adjusted EBIDTA of $266 million to $278 million and adjusted EPS of 87 cents to 93 cents.
Zacks Rank & Other Releases
Envision Healthcare carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Among the other stocks in the healthcare space, the bottom lines at UnitedHealth Group Inc. (UNH - Free Report) , Aetna Inc. (AET - Free Report) and Humana Inc. (HUM - Free Report) beat their respective second-quarter estimates.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>